Physician profile
Vani Bremjit
NPI 1568471589
$13,882.54
in general payments reported to CMS, 2019-2025
57 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $1,557 · 2021: $2,287 · 2022: $2,198 · 2023: $2,182 · 2024: $1,802 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,962 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,962.01 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,628.36 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Pfizer INC. | $1,432.70 | 2019-2025 | |
| Abbvie INC. | $1,048.06 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $847.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $834.52 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $621.56 | 2019-2022 | |
| Astellas Pharma US INC | $530.64 | 2019-2024 | Veozah |
| Novo Nordisk INC | $503.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $463.25 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $442.14 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $434.86 | 2019-2025 | |
| Lilly USA, LLC | $280.65 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $230.40 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $223.96 | 2019-2025 | Entyvio, Gattex |
| Abbott Laboratories | $188.19 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vani Bremjit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.